Engflag

Optineuron

Quick links to important sections

Optineuron

Optineuron_PL

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Optineuron

Quick Facts

Property Description
Active Ingredients Cyanocobalamin, Thiamine, Pyridoxine, Dexpanthenol, Niacinamide, Riboflavin
Forms Tablets, Solution for Injection (Ampoules)
Pharmacological Class B-Complex Vitamin Preparation, Nutritional Supplement
Common Use Prevention/Correction of B-vitamin deficiencies
Origin Synthetic Components

What Type of Medicine is Optineuron?

Optineuron is classified as a polyvitamin preparation and a Nutritional Supplement, specifically belonging to the B-Complex Vitamin Preparation pharmacological class. It is a fixed-dose combination product containing multiple essential Vitamin B Substances designed for systemic biological support. The preparation's active components are chemically defined and primarily synthetic in origin, combining key neurotropic agents such as Thiamine Hydrochloride (B1), Pyridoxine Hydrochloride (B6), and Cyanocobalamin (B12) with Dexpanthenol (B5), Niacinamide (B3), and Riboflavin (B2). The essential status of these B-group vitamins in human nutrition is well-established, and this formulation is particularly notable for combining the three neurotropic B-vitamins (B1, B6, B12) in doses pharmacologically supported for addressing deficiencies.

Optineuron: General Purpose and Benefit

The general purpose of Optineuron is to provide fundamental nutritional support by correcting or preventing deficiencies in essential B-group vitamins. These Vitamin B Substances function as vital coenzymes required for numerous metabolic processes throughout the body, including the efficient conversion of nutrients into energy. The formulation is specifically designed to support the nervous system, as B-group vitamins, including Cyanocobalamin and Thiamine, are critical for maintaining the structural integrity of nerve cells and optimal nerve function. This confirms that the complex of B-vitamins is generally useful for helping to maintain energy levels and supporting nerve health, which is a common use scenario for patients with confirmed B-vitamin hypovitaminosis. By supplying these essential nutrients, Optineuron helps maintain the overall balance and optimal function of both cellular metabolism and neurological integrity, particularly when dietary intake is insufficient or during periods of increased metabolic demand.

What side effects are possible with Optineuron?

Possible Side Effects and Safety Information

Official regulatory documents classify the potential adverse effects of this B-complex preparation primarily by the system or organ affected, including the Immune System, Skin and Subcutaneous Tissue, Gastrointestinal Disorders, and the Nervous System.

Adverse Reactions and Frequencies

Adverse reactions that are common or uncommon include mild and often transient effects such as nausea, vomiting, mild transient diarrhea, and skin reactions (e.g., rash, pruritus). More rare but serious reactions are documented, which include severe hypersensitivity events like anaphylactic shock and angioedema, particularly associated with parenteral administration of components like Thiamine ( B1).

Serious Adverse Reactions and Safety Constraints

Regulatory labeling specifies that serious events, while rare, have included pulmonary edema and congestive heart failure reported early in B12 treatment for severe deficiency. A key safety constraint relates to long-term exposure: prolonged use of high daily doses of Pyridoxine ( B6) is associated with the risk of sensory neuropathy.

Population-Specific Safety Notes

The preparation is explicitly contraindicated in patients with known hypersensitivity to any active ingredient. Furthermore, due to the risk of severe and swift optic atrophy, use is contraindicated in patients with early Leber's hereditary optic nerve atrophy. Specific cautions also apply to individuals with renal impairment due to the potential for aluminum toxicity with prolonged parenteral B12 use, as well as to patients with severe cardiac conditions.

Overdose and Emergency Response

Overdose and When to Seek Help

Optineuron Injection is a vitamin B-complex supplement that is typically administered in a clinical setting by a healthcare professional. For this reason, an overdose is considered less likely.

Potential Manifestations of Overdose

Symptoms that may be associated with an excessive amount of the injection include:

  • Neurological: Headache, dizziness, a sense of disorientation, insomnia, difficulty focusing, and sensitivity to bright lights.
  • Systemic: Nausea, as well as possible fluctuations in blood pressure (high or low).

Overdose risk related to the vitamin components, particularly Vitamin B6 (Pyridoxine), may also involve sensory neuropathy, which can cause numbness, tingling, and difficulties with walking, especially with high, long-term intake of B-complex supplements.

Overdose-Related Factors
Exposure-Related Note The risk is lower as administration is supervised by a doctor or nurse.
Concomitant Use Risk Using Optineuron with oral multivitamin supplements may increase the total intake of some vitamins, raising the potential for overdose.

Required Emergency Action

It is essential to seek immediate medical attention from a doctor or a nearby hospital if a person accidentally receives or takes an excessive amount of Optineuron Injection, or if any severe symptoms or unexpected side effects are experienced right after the administration. The healthcare provider will assess the situation and take necessary measures to manage a suspected overdose.

Therapeutic Uses of Optineuron

What Optineuron Treats: Main Uses and Benefits

Optineuron, which is commonly used to help with managing nutritional deficiencies involving B vitamins, may be part of symptomatic management for a range of conditions characterized by periods of heightened symptoms. This therapeutic approach is applied across domains where additional symptomatic support is needed, particularly in situations involving symptoms related to physical discomfort and systemic imbalance relevant in conditions characterized by periods of heightened symptoms.

The combined formulation plays a role in managing symptoms of increased neurological or muscular activity. The medicine may assist with addressing symptom clusters that become intense or disruptive, often used during phases when symptoms become more noticeable.

Clinical Context: Supportive Symptom Management

Quick Fact: Helps address symptom clusters that may become intense or disruptive

The supportive relief provided by the B-complex contributes to easing the overall symptom load. This means it supports patients during episodes of heightened discomfort and assists with maintaining functional stability when symptoms interfere with routine activities. The support provided helps ease the overall symptom burden.

Eligibility and Restrictions for Use

This medicine is generally intended for adults who do not have specific contraindications. Eligibility for use is determined by official regulatory documents based on individual patient profile and pre-existing conditions.

Contraindications (Must Not Use)

The most important constraint is a documented hypersensitivity or allergy to any active ingredient or component within the Optineuron formulation. Official labeling also typically contraindicates use in patients with acute myocardial infarction, erythremia/erythrocytosis, or certain thromboembolic conditions.

Restricted Use and Special Considerations

Use is restricted or requires caution in several specific patient groups:

  • Leber's Disease: Caution is advised, particularly with formulations containing high doses of Vitamin B12 (Cyanocobalamin), as it may potentially worsen optic atrophy.
  • Polycythemia Vera: Use requires caution due to the risk of stimulating red blood cell production.
  • Renal/Hepatic Impairment: Patients with existing kidney or liver disease require medical consultation and caution, as limited data is available.
  • Pregnancy and Lactation: Use in pregnant or breastfeeding individuals requires consultation with a healthcare professional to assess the balance of benefits versus potential risks, as comprehensive safety data is often limited.
  • Pediatric Use: The safety and effectiveness of the injection formulation in children, particularly those under 11 years of age, have not been fully established, limiting its use in this population.

Use is thus officially allowed only in the absence of these specific high-risk conditions and required cautions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes documented interaction patterns for the B-complex components of Optineuron, strictly based on official regulatory labeling.

Contraindications and Pharmacodynamic Antagonism

Co-administration of the Pyridoxine (Vitamin B6) component is a formally contraindicated combination with Levodopa unless Levodopa is combined with a peripheral dopa-decarboxylase inhibitor. This is due to Pyridoxine antagonizing the effects of Levodopa. Additionally, Chloramphenicol may antagonize the expected hematopoietic response to the Cyanocobalamin (Vitamin B12) component, and several other antibiotics may have their activity decreased by co-administered B-vitamins.

Exposure Alteration and Absorption Constraints

Interactions documented to alter exposure include Phenytoin, where co-administration of Pyridoxine can result in decreased plasma concentrations of the anticonvulsant. The antituberculosis agent Isoniazid and Hydralazine are officially noted as increasing the body's requirement for Pyridoxine. Several anticonvulsants, along with agents such as Colchicine, may impair the absorption of Cyanocobalamin. Chronic heavy alcohol intake is also documented as potentially producing malabsorption of B12.

Timing and Population Notes

To prevent the destruction of B12 by Ascorbic Acid (Vitamin C), official labeling mandates timing separation—large amounts of Vitamin C must be avoided within one hour of oral B12 administration. Furthermore, women taking oral contraceptives are documented to potentially exhibit increased Pyridoxine requirements, and prolonged administration of parenteral formulations in patients with impaired kidney function carries a documented risk of aluminum toxicity from excipients.

Mechanism of Action

Optineuron is a combination of B-vitamins that facilitates several key intracellular processes. Specifically, the high concentration of Thiamine pyrophosphate (TPP) acts as a coenzyme to alpha-ketoglutarate dehydrogenase, regulating specific steps in the tricarboxylic acid (TCA) cycle for cellular energy metabolism. Pyridoxine ( B6) and Cyanocobalamin ( B12) act synergistically at the cellular level to maintain the integrity of neuronal membranes. These components contribute to the structural stability of the myelin sheath via their required role in lipid and protein synthesis. Additionally, the components participate in S-adenosylmethionine (SAMe) cycle regulation, which facilitates crucial methylation reactions necessary for gene expression and wider physiological modulation.

Dosage and Administration Information

Optineuron is utilized according to a defined administration protocol that varies based on the dosage form and the phase of the support regimen. The preparation is officially available for oral use as tablets, and for parenteral use as a solution for injection. The injection may be administered via the intramuscular (IM) or intravenous (IV) routes. Administration of the parenteral form is restricted to a supervised clinical environment and must be performed by a healthcare professional, with self-administration strictly forbidden.

Official Administration Protocol

Instruction Detail
Parenteral Routes Intramuscular (IM) injection or slow Intravenous (IV) injection.
Dosing Volume The standard therapeutic dose for the injection is typically in the range of 1 to 2 mL per administration.
IV Preparation The high-concentration solution must be diluted with an appropriate parenteral solution when administered intravenously.
Initial Phase Frequency Administration is typically performed daily or on alternate days for an initial course, such as 6 to 14 days.
Maintenance Schedule Following the initial course, the schedule transitions to an intermittent maintenance phase, commonly weekly or monthly

This usage pattern establishes a short-term intensive phase followed by a long-term maintenance plan. For populations such as pediatric patients, dosage is not standardized and requires professional calculation based on body weight. If a dose is missed, patients are officially instructed to contact a healthcare professional immediately and are advised not to double the next scheduled administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Optineuron

The research base for Optineuron, a polyvitamin preparation, is structured around its components’ role in nutritional status and their evaluation in conditions involving nerve and muscle function. Research highlights what is known — and what is still uncertain — and findings describe group patterns, not personal outcomes.

Evidence for Outcomes Studied in B-Vitamin Deficiencies

The initial research exploring Optineuron's components focuses on their role as essential nutrients in the study context. These investigations were used in research exploring the influence of B-vitamin replacement on biochemical markers (like blood values) and other physical measurements in individuals with confirmed deficiencies or those identified with risk factors, such as issues with nutrient absorption. This section will summarize the body of research, including clinical guidelines and systematic reviews, where research examines outcomes in deficiency states (Hypovitaminosis).

Research describes patterns of change in blood parameters that were observed in some studies following supplementation. Evidence also highlights that research observes long-term or lifelong monitoring protocols to maintain required blood values in the context of severe, long-standing B-vitamin deficiencies.

Evidence for Symptoms Explored in Neuro-Musculoskeletal Conditions

Optineuron was studied for its neurotropic components ( B1 , B6 , and B12) in evaluating outcomes related to physical discomfort and outcomes reflecting daily functioning. These studies explored how symptoms were observed in adult populations with mild to moderate Peripheral Neuropathy (PN), as well as those with acute musculoskeletal pain.

Findings describe patterns observed in these studies regarding changes in nerve-related outcomes describing perceived discomfort over defined time intervals. In research involving acute pain, studies reported that when the B-vitamin combination was observed in combination with standard anti-inflammatory treatments (NSAIDs), data show patterns related to treatment duration and symptom scores that were different than NSAIDs used alone. Evidence is limited for the B-vitamin combination as a stand-alone symptomatic therapy in pain.

Understanding Research Gaps and Uncertainty

A major gap is that most symptomatic research was studied for the three-vitamin neurotropic combination ( B1 , B6 , and B12), and the evidence specifically examining the full six-vitamin Optineuron formulation is limited. Comparative evidence is lacking for the B-vitamin combination versus alternative treatments when used alone for non-deficiency conditions, and long-term effects are not fully established for many symptomatic outcomes.

Frequently Asked Questions (FAQ)

Common questions about Optineuron (FAQ)

Q: What is Optineuron Injection used for?

A: Optineuron Injection belongs to a class of medications called nutritional supplements and is primarily used to address nutritional deficiencies, particularly those related to the B-complex vitamins. It is also used to support the health of the nervous system.

Q: How does Optineuron Injection work?

A: Optineuron Injection is a combination of six essential B vitamins and related compounds, including Thiamine (Vitamin B1), Riboflavin (Vitamin B2), Nicotinamide (Vitamin B3), D-Panthenol (a form of Vitamin B5), Pyridoxine (Vitamin B6), and Cyanocobalamin (Vitamin B12). These components work together to provide essential nutrients that help to:

  • Boost the immune system.
  • Increase the body's metabolism.
  • Support the proper functioning of the nervous system.
  • Aid in the production of red blood cells.
  • Improve the body's absorption of iron.

Q: What are the common side effects of Optineuron Injection?

A: The most frequently reported side effects of Optineuron Injection are generally localized and may include:

  • Rash or redness.
  • Pain.
  • Itching.
  • Swelling at the injection site.

Consult your doctor if any of these side effects persist or worsen.

Q: Is it safe to take other nutritional supplements along with Optineuron Injection?

A: Avoid taking more than one multivitamin product at the same time, unless specifically advised by your doctor. Taking similar nutritional supplements concurrently may increase the risk of a vitamin overdose or other serious side effects. Always consult your doctor before taking any other supplements while receiving Optineuron Injection.

Q: Should I use Optineuron Injection if I am pregnant or breastfeeding?

A: You must consult a doctor before receiving Optineuron Injection if you are pregnant, planning a pregnancy, or breastfeeding. Information regarding its use during these times is limited. Your doctor will assess your specific health condition to determine if the treatment is necessary and appropriate for you.

Q: What are the precautions I need to take during Optineuron Injection treatment?

A: You should avoid taking any other medicine, including supplements and herbal products, without first consulting your prescribing doctor. Furthermore, you should inform your doctor immediately if you experience any signs of an allergic reaction, such as a rash, shortness of breath, or skin discoloration.

How should Optineuron be stored and disposed of?

How to Store and Dispose of Optineuron

Official regulatory information outlines specific requirements for storing and disposing of Optineuron to maintain its stability and ensure safety.

Storage Conditions

The product must be stored under controlled conditions to protect its integrity. Keep Optineuron out of the reach of children and pets at all times. Storage temperature requirements mandate keeping the medicine below 30 C or within the range of 15 C to 25 C. The medicine must be kept in its original container and protected from light and moisture.

Disposal Requirements

Do not use the medicine after the labeled expiry date has passed. If the product is supplied in a form intended for single-use, any unused portion must be discarded immediately. Disposal of any unused or expired medicine and waste material must be done strictly according to local requirements or as directed by a healthcare provider.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Optineuron found in:

A-Z Index: